Cancer Control (Sep 2024)

Survival Dynamics in Advanced Ovarian Cancer: R2 Resection Versus No-Surgery Paths Explored

  • Konstantinos Pitsikakis MD,
  • Diederick DeJong MBBCh, PhD, MSc,
  • Konstantinos Kitsos-Kalyvianakis MD,
  • Marios Evangelos Mamalis BA, MSc,
  • Michela Quaranta MBChB, MRCOG, MD,
  • Aishath Shavee MBChB,
  • Alina Wahab MBChB,
  • Amudha Thangavelu MBChB, MRCOG, MD,
  • Timothy Broadhead MBChB, MRCOG, MD,
  • David Nugent MBChB, MRCOG, MD,
  • Evangelos Kalampokis BA, PhD,
  • Alexandros Laios MD, PhD, Postdoc(Ox)

DOI
https://doi.org/10.1177/10732748241285480
Journal volume & issue
Vol. 31

Abstract

Read online

Background Cytoreductive surgery is critical for optimal tumor clearance in advanced epithelial ovarian cancer (EOC). Despite best efforts, some patients may experience R2 (>1 cm) resection, while others may not undergo surgery at all. We aimed to compare outcomes between advanced EOC patients undergoing R2 resection and those who had no surgery. Methods Retrospective data from 51 patients with R2 resection were compared to 122 patients with no surgery between January 2015 and December 2019 at a UK tertiary referral centre. Progression-free survival (PFS) and overall survival (OS) were the study endpoints. Principal Component Analysis and Term Frequency – Inverse Document Frequency scores were utilized for data discrimination and prediction of R>2 cm from computed tomography pre-operative reports, respectively. Results No statistical significance was observed, except for age (73 vs 67 years in the no- surgery vs R2 group, P : .001). Principal Components explained 34% of data variances. Reasons for no surgery included age, co-morbidities, patient preference, refractory disease, patient deterioration or disease progression, and absence of measurable intra- abdominal disease). The median PFS and OS were 12 and 14 months for no-surgery, vs 14 and 26 months for R2 ( P : .138 and P : .001, respectively). Serous histology and performance status independently predicted PFS in both no-surgery and R2 cohorts. In the no-surgery cohort, serous histology independently predicted OS, while in the R2 cohorts, both serous histology and adjuvant chemotherapy were independent prognostic features for OS. The bi-grams “abdominopelvic ascites” and “solid omental” were amongst those best discriminating between R>2 cm and R1-2 cm. Conclusions R2 resection and no-surgery cohorts displayed unfavourable prognosis with a notable degree of uniformity. When cytoreduction results in suboptimal results, the survival benefit may still be higher compared to those who underwent no surgery.